The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress

References

• de LeceaLKilduffTSPeyronCThe hypocretins: hypothalamus-specific peptides with neuroexcitatory activityProc Natl Acad Sci U S A19989513223279419374
   PubMed Web of Science ®Google Scholar
• SakuraiTOrexins and orexin receptors: implication in feeding behaviorRegul Pept1999851253010588447
   PubMedGoogle Scholar
• HungsMMignotEHypocretin/orexin, sleep and narcolepsyBioessays200123539740811340621
   PubMed Web of Science ®Google Scholar
• MahliosJDe la Harrán-AritaAKMignotEThe autoimmune basis of narcolepsyCurr Opin Neurobiol201323576777323725858
   PubMed Web of Science ®Google Scholar
• NishinoSRipleyBOvereemSLow cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsyAnn Neurol200150338138811558795
   PubMed Web of Science ®Google Scholar
• FunatoHTsaiALWillieJTEnhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivityCell Metab200991647619117547
   PubMed Web of Science ®Google Scholar
• RohJHJiangHFinnMBPotential role of orexin and sleep modulation in the pathogenesis of Alzheimer’s diseaseJ Exp Med2014211132487249625422493
   PubMed Web of Science ®Google Scholar
• KukkonenJPRecent progress in orexin/hypocretin physiology and pharmacologyBiomol Concepts20123544746325436549
   PubMedGoogle Scholar
• WB&A Market Research2005Sleep in America pollWashington, DCNational Sleep Foundation2005155 Available from: https://sleepfoundation.org/sites/default/files/2005_summary_of_findings.pdf
   Google Scholar
• PatelKVAspesiAVEvoyKESuvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomniaAnn Pharmacother201549447748325667197
   PubMed Web of Science ®Google Scholar
• NagaharaTSaitohTKutsumuraNDesign and synthesis of non-peptide, selective orexin receptor 2 agonistsJ Med Chem201558207931793726267383
   PubMed Web of Science ®Google Scholar
• Schutte-RodinSBrochLBuysseDDorseyCSateiaMClinical guideline for the evaluation and management of chronic insomnia in adultsJ Clin Sleep Med20084548750418853708
   PubMed Web of Science ®Google Scholar
• von EconomoCSleep as a problem of localizationJ Nerv Ment Dis193071315
   Google Scholar
• SakuraiTAmemiyaAIshiiMOrexins and orexins receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behaviorCell1998925735859491897
   PubMed Web of Science ®Google Scholar
• NunezARodrigo-AnguloMLDe AndresIGarzonMHypocretin/orexin neuropeptides: participation in the control of sleep-wakefulness cycle and energy homeostasisCurr Neuropharmacol200971505919721817
   PubMed Web of Science ®Google Scholar
• MiedaMHasegawaEKisanukiYYSintonCMYanagisawaMSakuraiTDifferential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleepJ Neurosci201131176518652621525292
   PubMed Web of Science ®Google Scholar
• WillieJTChemelliRMSintonCMDistinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processesNeuron200338571573012797957
   PubMed Web of Science ®Google Scholar
• RipleyBFujikiNOkuraMMignotENishinoSHypocretin levels in sporadic and familial cases of canine narcolepsyNeurobiol Dis20018352553411442359
   PubMed Web of Science ®Google Scholar
• WinrowCGotterACoxCPromotion of sleep by suvorexant – a novel dual orexin receptor antagonistJ Neurogenet2011251–2526121473737
   PubMed Web of Science ®Google Scholar
• HerringJWSnyderEBuddKOrexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexantNeurology2012792265227423197752
   PubMed Web of Science ®Google Scholar
• SunHKennedyWPDarrenWEffects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy menSleep20133625926723372274
   PubMed Web of Science ®Google Scholar
• MichelsonDSnyderEParadisESafety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trialLancet Neurol20141346147124680372
   PubMed Web of Science ®Google Scholar
• HerringJConnorKSnyderESuvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trialsBiol Psychiatry201679213614825526970
   PubMed Web of Science ®Google Scholar
• ColemanPJCoxCDBreslinMJDiscovery and characterization of OX2R/OX1R and OX2R antagonists for the treatment of sleep disordersACS Natl Mtg2014
   Google Scholar
• BonaventurePSheltonJYunSCharacterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomniaJ Pharmacol Exp Ther2015354347148226177655
   PubMed Web of Science ®Google Scholar
• RoeckerAJCoxCDColemanPJOrexin receptor antagonists: new therapeutic agents for the treatment of insomniaJ Med Chem201659250453026317591
   PubMed Web of Science ®Google Scholar
• BetticaPSquassanteLZamunerSNucciGDanker-HopfeHRattiEThe orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomniaSleep20123581097110422851805
   PubMed Web of Science ®Google Scholar
• ChabiAZhangYJacksonSRandomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxisCephalagia2015355379388
   PubMed Web of Science ®Google Scholar
• DuxonMSStrettonJStarrKEvidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvementPsychopharmacology (Berl)2001153220320911205420
   PubMed Web of Science ®Google Scholar
• ShoblockJRWeltyNAluisioLSelective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatementPsychopharmacology (Berl)2011215119120321181123
   PubMed Web of Science ®Google Scholar
• SteinerMAGatfieldJBrisbare-RochCDiscovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1selective antagonistChemMedChem20138689890323589487
   PubMed Web of Science ®Google Scholar
• BourginPZeitzerJMMignotECSF hypocretin-1 assessment in sleep and neurological disordersLancet Neurol20087764966218565458
   PubMed Web of Science ®Google Scholar
• NevsimalovaSPiskoJBuskovaJNarcolepsy: clinical differences and association with other sleep disorders in different age groupsJ Neurol2013260376777523070467
   PubMed Web of Science ®Google Scholar
• OhayonMMNarcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general populationSleep Med201314648849223643648
   PubMed Web of Science ®Google Scholar
• BlackJReavenNLFunkSEThe Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findingsSleep Med201415552252924768358
   PubMed Web of Science ®Google Scholar
• NishinoSRipleyBOvereemSLammersGJMignotEHypocretin (orexin) deficiency in human narcolepsyLancet2000355394010615891
   PubMed Web of Science ®Google Scholar
• FujikiNYoshidaYRipleyBMignotENishinoSEffects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dogSleep20032695395914746374
   PubMed Web of Science ®Google Scholar
• HeifetzABodkinMJBigginPCDiscovery of the first selective, nonpeptidic orexin 2 receptor agonistsJ Med Chem201558207928793026375584
   PubMed Web of Science ®Google Scholar